Leap Therapeutics (Nasdaq:LPTX) - Cotización, noticias y análisis

Resumen de acción LPTX

Leap Therapeutics, Inc. es una empresa biofarmacéutica que adquiere y desarrolla terapias con anticuerpos para el tratamiento del cáncer.

Acerca de la empresa

LPTX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Leap Therapeutics, Inc.

BioAtla

NasdaqGM:BCAB

US$148.6m

Ovid Therapeutics

NasdaqGS:OVID

US$212.4m

Entera Bio

NasdaqCM:ENTX

US$87.6m

I-Mab

NasdaqGM:IMAB

US$144.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Leap Therapeutics
Historical stock prices
Current Share Price	US$2.99
52 Week High	US$10.20
52 Week Low	US$1.24
Beta	0.59
1 Month Change	-12.32%
3 Month Change	-7.72%
1 Year Change	-29.65%
3 Year Change	-79.80%
5 Year Change	-80.26%
Change since IPO	-96.20%

Noticias y actualizaciones recientes

Recent updates

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Mar 13

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

Mar 03

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

Jan 27

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Dec 23

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Nov 18

Rentabilidad de los accionistas

	LPTX	US Biotechs	Mercado US
7D	-5.7%	1.3%	3.3%
1Y	-29.6%	3.0%	25.0%

Rentabilidad vs. Industria: LPTX obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del -2.3%.

Rentabilidad vs. Mercado: LPTX obtuvo unos resultados inferiores a los del mercado US, que fue del 19.3% el año pasado.

Volatilidad de los precios

Is LPTX's price volatile compared to industry and market?
LPTX volatility
LPTX Average Weekly Movement	14.8%
Biotechs Industry Average Movement	11.4%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de LPTX ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de LPTX(15%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2011	54	Doug Onsi	www.leaptx.com

Leap Therapeutics, Inc, empresa biofarmacéutica, adquiere y desarrolla terapias de anticuerpos para el tratamiento del cáncer. Sus principales productos candidatos incluyen DKN-01, un anticuerpo monoclonal que inhibe la proteína 1 relacionada con Dickkopf, que se encuentra en múltiples ensayos clínicos en curso para tratar cánceres esofagogástricos y ginecológicos; y FL-301, un anticuerpo monoclonal que se dirige a células que expresan Claudin18.2 en su superficie celular y se encuentra en ensayo clínico de fase II, así como dos programas preclínicos de anticuerpos, FL-302 y FL-501. Leap Therapeutics, Inc. tiene un acuerdo de opción y licencia con NovaRock, Adimab y BeiGene, Ltd.

Resumen de fundamentos de Leap Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Leap Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de LPTX
Capitalización bursátil	US$114.41m
Beneficios(TTM)	-US$81.41m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-1.4x

Ratio precio-beneficio (PE)

¿Está LPTX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de LPTX
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$81.41m
Beneficios	-US$81.41m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.13
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado LPTX a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción LPTX

Recompensas

Análisis de riesgos

Competidores de Leap Therapeutics, Inc.

NasdaqGM:BCAB

US$148.6m

NasdaqGS:OVID

US$212.4m

NasdaqCM:ENTX

US$87.6m

NasdaqGM:IMAB

US$144.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Recent updates

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Price target decreased by 10.0% to US$2.70

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.

Price target decreased to US$3.60

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces First Patient Enrolled in Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 Distinguish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

First half 2022 earnings released

Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05

Price target decreased to US$4.40

Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers

Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022

Consensus forecasts updated

Leap Therapeutics, Inc. to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

Consensus revenue estimates increase by 99%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Leap Therapeutics: Waiting For One More Leap

Leap Therapeutics to Present Positive New Data from the Distinguish Study of DKN-01 Plus Tislelizumab at the Asco GI Cancers Symposium

We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

Insufficient new directors

Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020)

Leap Therapeutics: All On The Line

Price target increased to US$4.50

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Leap Therapeutics to Present New Data from the Distinguish Study of Dkn-01 Plus Tislelizumab At the Esmo 2021 Congress

Price target decreased to US$4.00

First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020)

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Consensus forecasts updated

Consensus forecasts updated

Leap Therapeutics, Inc. Provides DKN-01 Development Update

Revenue and earnings miss expectations

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

New 90-day high: US$2.63

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

New 90-day high: US$2.42

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

New 90-day high: US$2.37

Analysts update estimates

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)